VIGL — Vigil Neuroscience Cashflow Statement
0.000.00%
Last trade - 00:00
- $101.85m
- -$16.09m
- 23
- 35
- 17
- 14
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -28.5 | -43.3 | -68.3 | -82.6 |
Depreciation | ||||
Non-Cash Items | 22.5 | 3.27 | 6.41 | 8.78 |
Unusual Items | ||||
Purchased R&D | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.85 | 0.642 | -3.33 | 3.1 |
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Cash from Operating Activities | -5.18 | -39.3 | -65.1 | -70.4 |
Capital Expenditures | 0 | -0.204 | -0.921 | -0.674 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | -0.5 | 0 | — | -64.5 |
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -0.5 | -0.204 | -0.921 | -65.1 |
Financing Cash Flow Items | 5 | -1.89 | 0 | — |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 29.8 | 108 | 161 | 0.888 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 24.2 | 68.2 | 95.2 | -135 |